Drugs / Aritinercept
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07596901 | Apr 2026 → Mar 2029 expected | generalized myasthenia gravis | Aurinia Pharmaceuticals Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-30 | Aurinia Pharmaceuticals Inc. | Results Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) auriniapharma.com ↗
Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-30 | Aurinia Pharmaceuticals Inc. | Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) auriniapharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aritinercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07596901 ↗ |
| Action | Inhibit | “Aritinercept, a Dual BAFF/APRIL Inhibitor” NCT07596901 ↗ |
| Route | Subcutaneous | “For subcutaneous injection” NCT07596901 ↗ |